Literature DB >> 28081026

The Effect of Nebulized Glycopyrrolate on Posterior Drooling in Patients with Brain Injury: Two Cases of Different Brain Lesions.

Zee-Ihn Lee1, Kwang Jae Yu, Dae Hee Lee, Seong Kyung Hong, Seung Beom Woo, Jong Min Kim, Donghwi Park.   

Abstract

Posterior drooling, which can lead to substantial respiratory morbidity, including unexplained lung diseases and recurrent pneumonia, is an important issue in the rehabilitation unit. There are various treatment options for posterior drooling, including pharmacologic therapy, oral motor or behavioral therapy, biofeedback, local glandular injection of botulinum toxin, irradiation, and surgery. Among them, nebulized glycopyrrolate has the following advantages: It is noninvasive and is relatively free of central adverse effects because it does not cross the blood-brain barrier unlike other anticholinergics. Although there has been one case report regarding the effectiveness of nebulized glycopyrrolate for drooling in a motor neuron patient, there have not been any reports on its effectiveness for posterior drooling. Herein, we report two cases (an 82-year-old male bilateral hemiplegic stroke patient and a 1-year-old female cerebral palsy infant with bilaterally spastic hemiplegia of posterior drooling treated with nebulized glycopyrrolate) and identify salivary aspiration and the effect of nebulized glycopyrrolate using radionuclide salivagram. Considering its advantages and effectiveness, nebulized glycopyrrolate should be considered as one of the reliable methods to manage posterior drooling in patients with impaired cognition or swallowing difficulties, such as severe brain injury.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28081026     DOI: 10.1097/PHM.0000000000000669

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  7 in total

Review 1.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

2.  The Correlation Between Clinical Characteristics and Radionuclide Salivagram Findings in Patients With Brain Lesions: A Preliminary Study.

Authors:  Donghwi Park; Seung Beom Woo; Dae Hee Lee; Kwang Jae Yu; Ju Young Cho; Jong Min Kim; Zeeihn Lee
Journal:  Ann Rehabil Med       Date:  2017-12-28

3.  Treatment of Ramsay-Hunt's syndrome with multiple cranial nerve involvement and severe dysphagia: A case report.

Authors:  Jong Min Kim; Zeeihn Lee; Seungwoo Han; Donghwi Park
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Clinical characteristics of dysphagic stroke patients with salivary aspiration: A STROBE-compliant retrospective study.

Authors:  Kwang Jae Yu; Donghwi Park
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  The effect of radionuclide solution volume on the detection rate of salivary aspiration in the radionuclide salivagram: A STROBE-compliant retrospective study.

Authors:  Dae Hee Lee; Jong Min Kim; Zeeihn Lee; Donghwi Park
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Different clinical predictors of aspiration pneumonia in dysphagic stroke patients related to stroke lesion: A STROBE-complaint retrospective study.

Authors:  Kwang Jae Yu; Hyunseok Moon; Donghwi Park
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 7.  Therapy of Sialorrhea with Botulinum Neurotoxin.

Authors:  Wolfgang H Jost; Tobias Bäumer; Rainer Laskawi; Jaroslaw Slawek; Björn Spittau; Armin Steffen; Martin Winterholler; Ganesh Bavikatte
Journal:  Neurol Ther       Date:  2019-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.